Gilead Science (GILD) Followers Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gilead Science (GILD) Followers

GILD 125.67

+0.4%

9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Glenn Petersen who wrote (946)	4/29/2020 10:28:04 AM
From: A.J. Mullen	Read Replies (1) of 961

*They said 64.5% of the patients who received the shorter treatment course were discharged, compared with 53.8% of the group who were treated for 10 days.* Without a control however, the possibility exists that patients without resdemivir might have been discharged sooner than both groups.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next